Skip to main content

Table 1 Characteristics of Participants in U.S. Military HIV Natural History Study by Baseline CD4+ Strata at HAART Initiation

From: Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort

  CD4+ (cells/mm3) at HAART start  
  ≤200 201-349 350-499 ≥500 Total
  (N = 419) (N = 580) (N = 493) (N = 354) (N = 1846)
Male 397 (95%) 566 (98%) 470 (95%) 337 (95%) 1770 (96%)
Race/ethnicity      
   Caucasian 169 (40%) 255 (44%) 216 (44%) 172 (49%) 812 (44%)
   African American 199 (47%) 246 (42%) 211 (43%) 139 (39%) 795 (43%)
   Hispanic 38 (9%) 54 (9%) 49 (10%) 27 (8%) 168 (9%)
   Other 13 (3%) 25 (4%) 17 (3%) 16 (5%) 71 (4%)
Year of HAART start *      
   1995-1999 311 (74%) 289 (50%) 298 (60%) 245 (69%) 1143 (62%)
   2000-2003 43 (10%) 104 (18%) 97 (20%) 68 (19%) 312 (17%)
   2004-2008 65 (16%) 187 (32%) 98 (20%) 41 (12%) 391 (21%)
Median age at      
   HAART start (IQR) * 36 (31, 42) 34 (29, 39) 34 (28, 39) 34 (29, 39) 34 (29, 40)
CD4+ nadir (cells/mm3) *      
   ≤200 419 (100%) 83 (15%) 20 (4%) 10 (3%) 532 (29%)
   201-349 0 (0%) 497 (86%) 180 (37%) 58 (16%) 735 (40%)
   350-499 0 (0%) 0 (0%) 293 (59%) 96 (27%) 389 (21%)
   ≥500 0 (0%) 0 (0%) 0 (0%) 190 (54%) 190 (10%)
Baseline VL at HAART start (copies/ml) *      
   <1000 17 (4%) 37 (6%) 59 (12%) 65 (18%) 178 (10%)
   1,000-9,999 25 (6%) 111 (19%) 107 (22%) 92 (26%) 335 (18%)
   10,000-99,999 156 (37%) 290 (50%) 231 (47%) 131 (37%) 808 (44%)
   ≥100,000 170 (41%) 117 (20%) 72 (15%) 54 (15%) 413 (22%)
   Missing 51 (12%) 25 (4%) 24 (5%) 12 (3%) 112 (6%)
AIDS diagnosis prior to      
   HAART * 116 (28%) 24 (4%) 19 (4%) 7 (2%) 166 (9%)
On ART prior to HAART * 277 (66%) 217 (37%) 221 (45%) 146 (41%) 861 (47%)
Median years HIV SC to      
   HAART start (IQR) * 6.8 (3.5,10.1) 3.2 (1.3,7.3) 3.3 (1.4,7.2) 2.8 (1.0,7.2) 4.1 (1.4,8.4)
Median years post-HAART      
   follow-up (IQR) ** 4.9 (2.2,11.4) 4.5 (2.0,9.2) 6.0 (2.1,10.8) 6.1 (2.6,10.6) 5.5 (2.1, 10.5)
  1. * P < 0.001 **P = 0.001
  2. HAART = Highly active antiretroviral therapy; ART = Antiretroviral therapy;
  3. VL = HIV Viral load; IQR = Interquartile range; SC = Seroconversion;